GE HealthCare Technologies Inc. (GEHC) announced the publication of data that depicts its artificial intelligence (AI) models’ ability to accurately predict patient responses to immunotherapies.The study collected clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy. A pan-cancer sample's data revealed that the company’s AI models' accuracy ranged from 70% to 80%.Price PerformanceIn the past six months, GEHC shares have grown 40.9% compared with the industry’s rise of 1 ...